- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05972551
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Childrens Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6909
- Recruiting
- Perth Childrens Hospital
-
-
-
-
-
Linz, Austria, 4020
- Recruiting
- Kepler Universitaetsklinikum GmbH
-
-
-
-
-
Leuven, Belgium, 3000
- Recruiting
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- Recruiting
- Centre Hospitalier Universitaire Sainte Justine
-
-
-
-
-
Paris Cedex 15, France, 75743
- Recruiting
- Hôpital Necker Enfants Malades
-
-
-
-
-
Budapest, Hungary, 1094
- Recruiting
- Semmelweis Egyetem
-
-
-
-
Okayama
-
Okayama-shi, Okayama, Japan, 700-8558
- Recruiting
- Okayama University Hospital
-
Okayama-shi, Okayama, Japan, 700-0013
- Recruiting
- Okayama Saiseikai Outpatient Center Hospital
-
-
Osaka
-
Izumi-shi, Osaka, Japan, 594-1101
- Recruiting
- Osaka Womens and Childrens Hospital
-
-
-
-
-
Lodz, Poland, 93-338
- Recruiting
- Instytut Centrum Zdrowia Matki Polki
-
Lodz, Poland, 91-738
- Recruiting
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny UMeds
-
-
-
-
-
Bratislava, Slovakia, 833 40
- Recruiting
- Narodny ustav detskych chorob
-
-
-
-
-
Madrid, Spain, 28009
- Recruiting
- Hospital Universitario Infantil Niño Jesus
-
-
Cataluña
-
Esplugues De Llorbregat, Cataluña, Spain, 08950
- Recruiting
- Hospital Sant Joan de Deu
-
-
Madrid
-
Getafe, Madrid, Spain, 28905
- Recruiting
- Hospital Universitario de Getafe
-
-
País Vasco
-
Baracaldo, País Vasco, Spain, 48903
- Recruiting
- Hospital de Cruces
-
-
-
-
-
Lausanne, Switzerland, 1011
- Recruiting
- Centre Hospitalier Universitaire Vaudois
-
-
-
-
-
Ankara, Turkey, 06500
- Recruiting
- Gazi Universitesi Tip Fakultesi
-
Istanbul, Turkey, 34890
- Recruiting
- Marmara Universitesi Tip Fakultesi Hastanesi
-
Trabzon, Turkey, 61080
- Recruiting
- Karadeniz Teknik Universitesi Hastanesi
-
-
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Childrens Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212-3157
- Recruiting
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures.
OR
- Participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent and the participant has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated.
- Ambulatory male and female children and adolescents, age 5 to <18 years, including ambulatory with assistance as defined in the pediatric osteogenesis imperfecta (OI) population.
Clinical diagnosis of OI, defined as clinical history consistent with type I, III, or IV OI as determined by presence of expected phenotype (examples include: facial shape, voice, blue sclera, dentinogenesis imperfecta, typical radiographic features, fracture pattern) and lack of additional features unrelated to type I, III, or IV OI (eg, blindness, mental retardation, neuropathy, and craniosynostosis).
o If familial, also must be autosomal dominant.
Meets at least one of the following:
- 3 or more fractures within the previous 2 years, or
- 1 or more nonvertebral fracture(s) within the previous 2 years and at least 1 prevalent vertebral fracture, or
- 2 or more prevalent vertebral fractures.
- Lumbar spine Z-score of ≤-1.0.
Exclusion Criteria:
Disease Related
- History of an electrophoresis pattern inconsistent with type I, III or IV OI.
- History of known mutation in a gene other than collagen type I alpha 1/collagen type I alpha 2 (COL1A1/COL1A2) causing OI or other metabolic bone disease.
- History of congenital dislocation of the radial head, interosseous membrane calcification, or exuberant callus formation.
Other Medical Conditions
- History of osteomalacia or rickets.
- Body weight less than 14 kg or greater than 90 kg.
- History of other bone diseases that affect bone metabolism (e.g., but not limited to osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis, osteopetrosis, hypophosphatasia).
- History of Kawasaki disease, rheumatic myocarditis, ischemic cardiomyopathy, inherited cardiomyopathies, nephrotic syndrome, familial hypercholesterolemia, stroke, or any thromboembolic disorder.
- Evidence of untreated or unhealed oral infections.
- Unhealed or planned invasive dental or tooth procedure as determined by treating dentist; removal of baby teeth is acceptable and not considered an invasive dental procedure.
- Unhealed fracture as defined by orthopedic opinion.
- Osteotomy, rodding surgery or spinal fusion surgery within 5-months prior to screening, or not yet healed per orthopedic surgeon.
- History of clinically significant valvular heart disease previously documented with local echocardiogram results.
Evidence of any of the following:
- Current hyper- or hypoparathyroidism (parathyroid hormone outside the normal range).
Renal disease: Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m^2 (calculated by the bedside Schwartz equation at screening) eGFR (mL/min/1.73 m^2) = 0.413 X (height/serum creatinine)
1. (Height is in centimeters, and serum creatinine is in mg/dL).
- Current hypocalcemia (albumin-adjusted serum calcium <lower limit of normal [LLN]) or hypercalcemia (albumin-adjusted serum calcium > upper limit of normal [ULN] of the laboratory's reference range).
- Serum vitamin D <20 ng/mL; rescreening for Vitamin D level < 20 ng/mL will be allowed, after adequate supplementation.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 1.5 x ULN.
- Total bilirubin (TBL) >1.5 x ULN (participants with Gilbert syndrome are eligible).
- Serum phosphorus < LLN for age.
- Symptoms associated with skull abnormalities such as basilar invagination, basilar impression or Chiari malformation (e.g., headache induced by coughing or straining for stool, visual disturbances, paresthesias or weakness).
- History of malabsorption (in children with serum albumin <LLN, malabsorption should be clinically ruled out by the investigator to confirm eligibility).
- History of long QT syndrome.
- History of malignancy.
- History of any solid organ or bone marrow transplant.
- History of hyper- or hypothyroidism, unless participant is on stable therapy > 6-months and has supporting laboratory documentation within 6-months prior to or at screening indicating normal serum thyroid-stimulating hormone (TSH) value.
- Known intolerance to calcium or vitamin D supplements.
- History of osteonecrosis of the jaw (ONJ).
Prior/Concomitant Therapy
- Prior treatment with:
- Romosozumab or other anti-sclerostin antibody within 12-months prior to screening.
- Fluoride or strontium for bone disease.
- Parathyroid hormone (PTH) or PTH derivatives within 12-months prior to screening.
- Denosumab within 12-months after the last injection prior to first dose of romosozumab.
- Administration of any of the following treatments within 3-months prior to screening:
- Systemic glucocorticoids (≥ 5.0 mg prednisone equivalent/day for more than 10 days) within 3-months prior to screening. Topical and inhaled glucocorticoids will be allowed.
- Growth hormone (participants on stable dose of growth hormone for at least 3-months prior to screening will be allowed).
- Calcitonin.
- Other bone active drugs including anticonvulsants (except gabapentin and benzodiazepines) and heparin (unless low molecular weight heparin).
- Chronic systemic ketoconazole, androgens (except participants who have received testosterone therapy for physiologic replacement in the setting of documented hormonal deficiency), adrenocorticotropic hormone (ACTH), cinacalcet, aluminum, lithium, protease inhibitors, gonadotropin-releasing hormone agonists.
- Use of concomitant medications that may prolong the corrected QT interval (eg, ondansetron, albuterol, sotalol, amiodarone, erythromycin, or clarithromycin). Refer to CredibleMeds.org for the complete list of medications which can impact QT interval.
Prior/Concurrent Clinical Study Experience
- Currently receiving treatment in another investigational device or drug study, or less than 2 years since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
Other Exclusions
- Positive blood screen for hepatitis B surface antigen (HbsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody (HepCAb).
- Participants with symptomatic human immunodeficiency virus (HIV) with bone involvement or those that have been in a serious clinical condition.
- Less than 2 evaluable vertebrae by dual-energy x-ray absorptiometry evaluation in the region of interest, L1-L4, as confirmed by the central imaging laboratory.
- Any planned major surgery, including skeletal surgery (eg, rodding surgery, spinal surgery) within the next 12-months from Day 1 that would interfere with study procedures or would require missing of any investigational product
- Female participants of childbearing potential unwilling to use a highly effective method of contraception during treatment and for an additional 3-months after the last dose of investigational product or non-investigational product.
- Female participants who are breastfeeding or who plan to breastfeed while on study through 3-months after the last dose of investigational product or non-investigational product.
- Female participants planning to become pregnant or donate eggs while on study through 3-months after the last dose of investigational product or non-investigational product.
- Female participants of childbearing potential with a positive pregnancy test assessed at Screening and/or Day 1 by a highly sensitive urine or serum pregnancy test.
- Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 3-months after the last dose of investigational product or non-investigational product.
- Male participants unwilling to abstain from donating sperm during treatment and for an additional 3-months after the last dose of investigational product or non-investigational product.
- Participant has known sensitivity to any of the products to be administered during dosing.
- Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the participant and investigator's knowledge.
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Romosozumab
Participants will receive romosozumab once a month (QM) for 12 months.
|
Subcutaneous (SC) injection
Other Names:
|
Active Comparator: Standard of Care Bisphosphonate
Participants will receive bisphosphonates per local standard of care treatment regimens, as determined by the investigator for 12 months.
|
Administration determined by investigator according to the local standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Clinical Fractures
Time Frame: 12 months
|
Clinical fractures include clinical vertebral fractures and nonvertebral fractures.
|
12 months
|
Number of Any Fractures
Time Frame: 12 months
|
Fractures include new and worsening vertebral compression fractures, whether clinically silent or manifest, and nonvertebral fractures.
|
12 months
|
Change from Baseline to 6 Months in Lumbar Spine BMD Z-score
Time Frame: Baseline and 6 months
|
Baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline to 12 Months in Lumbar Spine BMD Z-score
Time Frame: Baseline and 12 months
|
Baseline and 12 months
|
|
Change from Baseline to 6 Months in Total Hip BMD Z-score
Time Frame: Baseline and 6 months
|
Baseline and 6 months
|
|
Change from Baseline to 12 Months in Total Hip BMD Z-score
Time Frame: Baseline and 12 months
|
Baseline and 12 months
|
|
Change from Baseline to 6 Months in Femoral Neck BMD Z-score
Time Frame: Baseline and 6 months
|
Baseline and 6 months
|
|
Change from Baseline to 12 Months in Femoral Neck BMD Z-score
Time Frame: Baseline and 12 months
|
Baseline and 12 months
|
|
Number of Participants with Any Fractures
Time Frame: 12 months
|
12 months
|
|
Number of Participants with Clinical Fractures
Time Frame: 12 months
|
12 months
|
|
Number of Participants with New or Worsening Vertebral Fractures
Time Frame: 12 months
|
12 months
|
|
Number of Participants with Nonvertebral Fractures
Time Frame: 12 months
|
12 months
|
|
Number of New or Worsening Vertebral Fractures
Time Frame: 12 months
|
12 months
|
|
Number of Nonvertebral Fractures
Time Frame: 12 months
|
12 months
|
|
Number of Long Bone Fractures
Time Frame: 12 months
|
12 months
|
|
Change from Baseline in Child Health Questionnaire - Parent Version (CHQ-PF-50) Physical Summary Score
Time Frame: Baseline and 12 months
|
The CHQ-PF-50 measures how a child's condition affects their ability to function in daily life. The CHQ-PF-50 measures 50 items in the following domains: physical functioning, role/social limitations - physical, general health perceptions, bodily pain/discomfort, family activities, role/social limitations - emotional/behavioral, parent impact - time, parent impact - emotion, self-esteem, mental health, behavior, family cohesion, change in health. Each item is rated on a scale from "without any difficulty" to "unable to do". Total scores for each item are transformed to 0 - 100 scale, with lower scores indicating worse health states. Higher change from baseline scores indicate better or more positive health states. |
Baseline and 12 months
|
Change from Baseline in Childhood Health Assessment Questionnaire (CHAQ-CV) Disability Score
Time Frame: Baseline and 12 months
|
The CHAQ-CV measures how a child's condition affects their ability to function in daily life. The CHAQ-CV measures 50 items in the following domains: physical functioning, role/social limitations - physical, general health perceptions, bodily pain/discomfort, family activities, role/social limitations emotional/behavioral, self-esteem, mental health, behavior, family cohesion, change in health. Each item is rated on a scale from "without any difficulty" to "unable to do". Total scores for each item are transformed to 0 - 100 scale, with lower scores indicating worse health states. Higher change from baseline scores indicate better or more positive health states. |
Baseline and 12 months
|
Change from Baseline in the Wong-Baker Faces Pain Rating Scale
Time Frame: Baseline and 12 months
|
The Wong-Baker Faces Pain Rating Scale is a horizontal pain scale that consists of six hand-drawn faces that range from a smiling "no hurt" face with a score of 0 to a crying "hurts worst" face with a score of 10.
Greater change from baseline scores indicate greater pain experienced by the participant.
|
Baseline and 12 months
|
Serum Concentration of Romosozumab
Time Frame: Day 1 to Month 12
|
Day 1 to Month 12
|
|
Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs) at 12 Months
Time Frame: 12 months
|
Any clinically signification change from baseline in laboratory values and vital signs after first dose will be recorded as a TEAE.
|
12 months
|
Number of Participants with Anti-romosozumab Antibodies at 12 Months
Time Frame: 12 months
|
12 months
|
|
Number of Participants who Experience TEAEs from Month 12 to Month 15
Time Frame: Month 12 to Month 15
|
Any clinically signification change from baseline in laboratory values and vital signs after first dose will be recorded as a TEAE.
|
Month 12 to Month 15
|
Number of Participants with Anti-romosozumab Antibodies from Month 12 to Month 15
Time Frame: Month 12 to Month 15
|
Month 12 to Month 15
|
|
Number of Participants who Experience TEAEs at 15 Months
Time Frame: 15 months
|
Any clinically signification change from baseline in laboratory values and vital signs after first dose will be recorded as a TEAE.
|
15 months
|
Number of Participants with Anti-romosozumab Antibodies at 15 Months
Time Frame: 15 months
|
15 months
|
|
Number of Participants with a Narrowing from Baseline to 6 Months in the Intracranial Nerve Tract in the Cranium and Vault of the Skull
Time Frame: Baseline and 6 months
|
Measured in a subset of participants who receive cranial nerve computerized tomography (CT) scans.
|
Baseline and 6 months
|
Number of Participants with a Narrowing from Baseline to 12 Months in the Intracranial Nerve Tract in the Cranium and Vault of the Skull
Time Frame: Baseline and 12 months
|
Measured in a subset of participants who receive cranial nerve CT scans.
|
Baseline and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20200105
- 2023-503294-37 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteogenesis Imperfecta
-
Nationwide Children's HospitalCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IIUnited States
-
Ultragenyx Pharmaceutical IncMereo BioPharmaCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IV | Osteogenesis Imperfecta, Type IUnited States, Canada, Denmark, France, United Kingdom
-
Emory UniversityNot yet recruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta Type III
-
Novartis PharmaceuticalsCompletedOsteogenesis ImperfectaUnited States
-
Shriners Hospitals for ChildrenNovartisCompleted
-
AmgenTerminatedOsteogenesis Imperfecta (OI)Canada, Czechia, Spain, United Kingdom, United States, Italy, Hungary, Australia, Belgium, France, Germany, Poland
-
Istituto Ortopedico RizzoliRecruitingOsteogenesis ImperfectaItaly
-
Baylor College of MedicineRecruiting
-
SanofiRecruitingOsteogenesis ImperfectaUnited States, Australia, Canada, France
-
Ultragenyx Pharmaceutical IncMereo BioPharmaRecruitingOsteogenesis ImperfectaUnited States, Canada, Turkey, Argentina, Germany, Australia, Italy, Portugal, United Kingdom, Poland, France, Netherlands
Clinical Trials on Romosozumab
-
AmgenRecruitingPostmenopausal OsteoporosisIndia
-
Memorial Sloan Kettering Cancer CenterRecruitingMultiple Myeloma | OsteoporosisUnited States
-
UCB Biopharma SRLCompleted
-
AmgenUCB PharmaCompletedFracture HealingCanada, Italy, United States, Russian Federation, France, Germany, Hong Kong, Hungary, Australia, Bulgaria, Poland, Romania, Greece, Denmark, Estonia, India, New Zealand, United Kingdom, Latvia, Slovakia, Lithuania, Mexico, Norway
-
AmgenCompletedPostmenopausal OsteoporosisKorea, Republic of
-
AmgenCompleted
-
AmgenCompleted
-
AmgenCompletedOsteoporosis in MenUnited States, Belgium, Colombia, Czechia, Denmark, Japan, Mexico, Poland, Russian Federation, Switzerland